Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other financing activities (2016 - 2018)

Enanta Pharmaceuticals (ENTA) has disclosed Other financing activities for 7 consecutive years, with -$5.5 million as the latest value for Q2 2018.

  • For the quarter ending Q2 2018, Other financing activities changed N/A year-over-year to -$5.5 million, compared with a TTM value of -$5.5 million through Sep 2024, down 68.06%, and an annual FY2023 reading of $325000.0, changed N/A over the prior year.
  • Other financing activities was -$5.5 million for Q2 2018 at Enanta Pharmaceuticals, down from $2.2 million in the prior quarter.
  • Across five years, Other financing activities topped out at $2.2 million in Q1 2018 and bottomed at -$5.5 million in Q2 2018.
  • Average Other financing activities over 5 years is -$222.22, with a median of -$2000.0 recorded in 2016.
  • The sharpest move saw Other financing activities crashed 160.0% in 2015, then surged 1767.65% in 2016.
  • Year by year, Other financing activities stood at $1.9 million in 2014, then crashed by 100.16% to -$3000.0 in 2015, then soared by 33.33% to -$2000.0 in 2016, then tumbled by 12150.0% to -$245000.0 in 2017, then crashed by 2146.53% to -$5.5 million in 2018.
  • Business Quant data shows Other financing activities for ENTA at -$5.5 million in Q2 2018, $2.2 million in Q1 2018, and -$245000.0 in Q4 2017.